Logo image of LDL

Lydall Inc (LDL) Stock Fundamental Analysis

NYSE:LDL - New York Stock Exchange, Inc. -

62.09  +0.01 (+0.02%)

After market: 62.09 0 (0%)

Fundamental Rating

2

Taking everything into account, LDL scores 2 out of 10 in our fundamental rating. LDL was compared to 127 industry peers in the Machinery industry. LDL has a bad profitability rating. Also its financial health evaluation is rather negative. LDL is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LDL was profitable.

1.2 Ratios

Industry RankSector Rank
ROA -0.07%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Industry RankSector Rank
OM 1.94%
PM (TTM) -0.07%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

There is no outstanding debt for LDL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 3.11 indicates that LDL is not in any danger for bankruptcy at the moment.
A Debt/Equity ratio of 0.91 indicates that LDL is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Altman-Z 3.11
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

LDL has a Current Ratio of 1.95. This is a normal value and indicates that LDL is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.48 indicates that LDL should not have too much problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 1.95
Quick Ratio 1.48

More info and screens

6

3. Growth

3.1 Past

LDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1900.00%, which is quite impressive.
The Revenue has grown by 16.23% in the past year. This is quite good.
LDL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.81% yearly.
EPS 1Y (TTM)1900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%285.19%
Revenue 1Y (TTM)16.23%
Revenue growth 3Y3.04%
Revenue growth 5Y7.81%
Sales Q2Q%51.71%

3.2 Future

LDL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 406.52% yearly.
The Revenue is expected to grow by 11.38% on average over the next years. This is quite good.
EPS Next Y9392%
EPS Next 2Y939.47%
EPS Next 3Y541.91%
EPS Next 5Y406.52%
Revenue Next Year18.7%
Revenue Next 2Y11.55%
Revenue Next 3Y11.26%
Revenue Next 5Y11.38%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LDL Yearly Revenue VS EstimatesLDL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B
LDL Yearly EPS VS EstimatesLDL Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 4 6 8 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

LDL is valuated quite expensively with a Price/Earnings ratio of 68.99.
Compared to an average S&P500 Price/Earnings ratio of 27.41, LDL is valued quite expensively.
The Price/Forward Earnings ratio is 29.27, which means the current valuation is very expensive for LDL.
When comparing the Price/Forward Earnings ratio of LDL to the average of the S&P500 Index (35.19), we can say LDL is valued inline with the index average.
Industry RankSector Rank
PE 68.99
Fwd PE 29.27
LDL Price Earnings VS Forward Price EarningsLDL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 18.25
LDL Per share dataLDL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

LDL's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
LDL's earnings are expected to grow with 541.91% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y939.47%
EPS Next 3Y541.91%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for LDL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Lydall Inc

NYSE:LDL (9/30/2021, 8:04:00 PM)

After market: 62.09 0 (0%)

62.09

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners4.69%
Ins Owner Change0%
Market Cap1.12B
Analysts0
Price Target63.34 (2.01%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 68.99
Fwd PE 29.27
P/S 1.29
P/FCF N/A
P/OCF N/A
P/B 4.07
P/tB N/A
EV/EBITDA 18.25
EPS(TTM)0.9
EY1.45%
EPS(NY)2.12
Fwd EY3.42%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS48.02
BVpS15.26
TBVpSN/A
PEG (NY)0.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -0.07%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 1.94%
PM (TTM) -0.07%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover1.1
Health
Industry RankSector Rank
Debt/Equity 0.91
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.95
Quick Ratio 1.48
Altman-Z 3.11
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%285.19%
EPS Next Y9392%
EPS Next 2Y939.47%
EPS Next 3Y541.91%
EPS Next 5Y406.52%
Revenue 1Y (TTM)16.23%
Revenue growth 3Y3.04%
Revenue growth 5Y7.81%
Sales Q2Q%51.71%
Revenue Next Year18.7%
Revenue Next 2Y11.55%
Revenue Next 3Y11.26%
Revenue Next 5Y11.38%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A